Public Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals Image

[Louie41]

https://www.nytimes.com/2018/09/08/health/jose-baselga-cancer-memorial-sloan-kettering.html?rref=collection/sectioncollection/world&action=click&contentCollection=world&region=stream&module=stream_unit&version=latest&contentPlacement=9&pgtype=sectionfront

See also the related articles noted at the end of this article.

 

[Andy]

One of the world’s top breast cancer doctors failed to disclose millions of dollars in payments from drug and health care companies in recent years, omitting his financial ties from dozens of research articles in prestigious publications like The New England Journal of Medicine and The Lancet.

The researcher, Dr. José Baselga, a towering figure in the cancer world, is the chief medical officer at Memorial Sloan Kettering Cancer Center in New York. He has held board memberships or advisory roles with Roche and Bristol-Myers Squibb, among other corporations, has had a stake in start-ups testing cancer therapies, and played a key role in the development of breakthrough drugs that have revolutionized treatments for breast cancer.

And short version of the URL is https://www.nytimes.com/2018/09/08/health/jose-baselga-cancer-memorial-sloan-kettering.html

 

[Louie41]

Thanks, @Andy. I didn't have the mental wherewithal to do more than skim the article, let alone clean things up nicely the way you have.

 

[Lisa108]

At a conference this year and before analysts in 2017, he put a positive spin on the results of two Roche-sponsored clinical trials that many others considered disappointments, without disclosing his relationship to the company. Since 2014, he has received more than $3 million from Roche in consulting fees and for his stake in a company it acquired.

[my bold]